# Aquestive Therapeutics Inc. (AQST)

**Exchange:** NASDAQ  
**Market cap:** $450M  
**Price:** $4.21 (+5.51%)

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $45M | $26M | -$71M | -$84M | — |
| 2024 | $58M | $40M | -$31M | -$44M | — |
| 2023 | $51M | $30M | -$15M | -$8M | — |
| 2022 | $48M | $28M | -$42M | -$54M | — |
| 2021 | $51M | — | -$35M | -$71M | — |
| 2020 | $46M | $33M | -$43M | -$56M | — |
| 2019 | $53M | $32M | -$53M | -$66M | — |
| 2018 | $67M | — | -$49M | -$61M | — |
| 2017 | $67M | — | -$113,000 | -$9M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $160M | $194M | -$34M | $121M | $45M |
| 2024 | $101M | $162M | -$60M | $72M | $45M |
| 2023 | $57M | $164M | -$106M | $24M | $45M |
| 2022 | $57M | $176M | -$119M | $27M | — |
| 2021 | $62M | $144M | -$82M | $28M | — |
| 2020 | $63M | $111M | -$48M | $32M | $52M |
| 2019 | $78M | $85M | -$6M | $49M | $70M |
| 2018 | $87M | $77M | $10M | $61M | — |
| 2017 | $43M | $70M | -$26M | $17M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$52M | $562,000 | -$53M |
| 2024 | -$36M | $159,000 | -$36M |
| 2023 | -$6M | $995,000 | -$7M |
| 2022 | -$10M | $1M | -$11M |
| 2021 | -$33M | $913,000 | -$34M |
| 2020 | -$45M | $517,000 | -$46M |
| 2019 | -$60M | $663,000 | -$61M |
| 2018 | -$13M | $2M | -$15M |
| 2017 | $6M | $2M | $4M |

Source: [CompaniesByCap](https://companiesbycap.com/company/AQST)